

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3565477

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
KATALIN VARADI	01/08/2010
HANSPETER ROTTENSTEINER	01/07/2010
PETER TURECEK	01/11/2010
HANS-PETER SCHWARZ	01/19/2010
JUTTA SCHREINER	12/22/2009
RECEIVING PARTY DATA	
Name:	BAXTER HEALTHCARE S.A.
Street Address:	THURGAUERSTRASSE 130
Internal Address:	GLATTPARK
City:	OPFIKON
State/Country:	SWITZERLAND
Postal Code:	CH-8152
Name:	BAXTER INTERNATIONAL INC.
Street Address:	ONE BAXTER PARKWAY
City:	DEERFIELD
State/Country:	ILLINOIS
Postal Code:	60015
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	13795214
Application Number:	14078324
Application Number:	14549404
CORRESPONDENCE DATA	
Fax Number:	(214)978-3099
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2149783000
Email:	JESSICA.GREENWALD@BAKERMCKENZIE.COM
Correspondent Name:	PATENT DEPARTMENT
Address Line 1:	BAKER & MCKENZIE LLP
PATENT	

Address Line 2:	2001 ROSS AVENUE, SUITE 2300
Address Line 4:	DALLAS, TEXAS 75201

ATTORNEY DOCKET NUMBER:	BAXALTA 5510 DIV
--------------------------------	------------------

NAME OF SUBMITTER:	JESSICA W. GREENWALD
---------------------------	----------------------

SIGNATURE:	/Jessica W. Greenwald/
-------------------	------------------------

DATE SIGNED:	10/12/2015
---------------------	------------

Total Attachments: 3

source=Signed Assignment for US 12-630509_sched_vF#page1.tif

source=Signed Assignment for US 12-630509_sched_vF#page2.tif

source=Signed Assignment for US 12-630509_sched_vF#page3.tif

Baxter

ASSIGNMENT (Joint Inventors)

Serial No. US 61/120,202 Filed December 5, 2008 Attorney Docket No. BTERR 6602P1US
Serial No. US 12/630,509 Filed December 3, 2009 Attorney Docket No. BTERR 6602US

For good and valuable considerations, the receipt and sufficiency whereof are hereby acknowledged, we hereby assign to **BAXTER INTERNATIONAL INC.**, a corporation of Delaware, having a principal place of business at Deerfield, Illinois, its successors, legal representatives and assigns, and to **BAXTER HEALTHCARE S.A.**, a corporation of Switzerland, having a principal place of business at Zurich, Switzerland, its successors, legal representatives and assigns (hereinafter jointly referred to as "assignee") the entire right, title and interest throughout the world, to the extent not previously assigned to assignee, in our invention or improvements in

METHODS OF MEASURING ADAMTS13-MEDIATED IN VIVO CLEAVAGE OF VON WILLEBRAND FACTOR AND USES THEREOF

and, effective as of the date of filing, in the above listed application(s) for Letters Patent therefor, executed by each of us individually, and any and all other patent applications in any and all countries which have been or may hereafter be filed, either solely or jointly with others, on said invention or improvements, and in any and all Letters Patent of any country which may be obtained on any of the said applications, and in any reissue or extension thereof and any applications that claim priority thereto, including any regional and national stage applications.

We hereby authorize and request the patent offices of all countries to issue to the said assignee all patents that may issue on said invention or improvements. We hereby authorize and request the attorneys of record in said application to insert in this assignment the date and serial number and docket number of said applications when officially known.

We warrant ourselves to be the owners of the interest herein assigned and to have the right to make this assignment; and further warrant that there are no outstanding prior assignments, licenses, or other rights to any person or entity other than the assignee in the interest herein assigned.

For said considerations we hereby agree, upon the request and at the expense of said assignee, its successors, legal representatives and assigns, to execute any and all divisional, continuation, and renewal applications for said invention or improvements, and any necessary oath or supplemental oath or affidavit relating thereto, and any application for the reissue or extension of any Letters Patent that may be granted upon said application, including any regional and national stage applications that claim priority thereto, that said assignee, its successors, legal representatives and assigns may deem necessary or expedient, and for the said considerations we further agree, upon the request of said assignee, its successors, legal representatives and assigns, in the event of said application or any continuation or division thereof, or Letters Patent issued thereon, or any reissue or application for the reissue thereof becoming involved in interference, to cooperate to the best of our ability with said assignee, its successors, legal representatives and assigns in the matters of preparing and executing the preliminary statement and giving and producing evidence in support thereof.

We further agree to perform, upon such request, any and all affirmative acts, including but not limited to execution of any and all documents deemed necessary or expedient by the said assignee or its successors, legal representatives or assigns, to obtain Letters Patent, and vest all rights therein hereby conveyed in the said assignee, its successors, legal representatives and assigns whereby said Letters Patent will be held and enjoyed by the said assignee, its successors, legal representatives and assigns to the end of the term for which said Letters Patent may be granted as fully and entirely as the same would have been held and enjoyed by us if this assignment and sale had not been made, and for the said considerations we hereby also assign to said assignee, its successors, legal representatives and assigns the entire right, title and interest in said invention or improvements for any and all foreign countries and the right of priority for patent and utility model applications in all countries arising under any applicable international convention for the protection of industrial property and/or any internal priority legislation of such countries, and we further agree upon the request of said assignee, its successors, legal representatives and assigns to execute any and all documents that shall be required to be executed in connection with any and all applications for foreign Letters Patent therefor, including the prosecution thereof, and to execute any and all documents necessary to invest title in said foreign applications and patents in said assignee.

WITNESS our hand.

Baxter

**Signature Sheet
(Joint Inventors)**

Serial No. US 61/120.202 Filed December 5, 2008 Attorney Docket No. BTERR 6602P1US
Serial No. US 12/630.509 Filed December 3, 2009 Attorney Docket No. BTERR 6602US

**METHODS OF MEASURING ADAMTS13-MEDIATED IN VIVO CLEAVAGE
OF VON WILLEBRAND FACTOR AND USES THEREOF**

Inventor Name: <u>Katalin VARADI</u>	Inventor Name: <u>Hanspeter ROTTENSTEINER</u>
Date: <u>January, 08, 2010</u>	Date: <u>January, 07, 2010</u>
Signature: <u>Katalin Varadi</u>	Signature: <u>Hanspeter R. Rottensteiner</u>
Witness Name: <u>Susanne VEJDA</u>	Witness Name: <u>Sabine Mandl</u>
Date: <u>January, 08, 2010</u>	Date: <u>January, 07, 2010</u>
Signature: <u>SVejda</u>	Signature: <u>Sabine Mandl</u>

Inventor Name: <u>Peter TURECEK</u>	Inventor Name: <u>Hans-Peter SCHWARZ</u>
Date: <u>Jan 11, 2010</u>	Date: <u>11.01.10</u>
Signature: <u>Peter Turecek</u>	Signature: <u>Hans-Peter Schwarz</u>
Witness Name: <u>Manuela LEIBRECHT</u>	Witness Name: <u>Mag. Christine Pavesicz</u>
Date: <u>Jan. 11, 2010</u>	Date: <u>19.1.2010</u>
Signature: <u>Manuela Leibrecht</u>	Signature: <u>Christine Pavesicz</u>

Inventor Name: Jutta SCHREINER

Date: December, 23, 2009

Signature: Jutta Schreiner

Witness Name: Eveline Gruber

Date: December, 22, 2009

Signature: Eveline Gruber

SCHEDULE A

Family	Case	Country	Appl No	Appl Date	Patent No	Issue Date	Title	Owner
5510	BP5510USD2	United States	14/078324	12-Dec-2013	9,110,085	18-Aug-15	METHODS OF TESTING EFFECTIVENESS OF A TREATMENT FOR THROMBOTIC THROMBOCYTOPENIC PURPURA BY MEASURING ADAMTS 13-MEDIATED IN VIVO CLEAVAGE OF VON WILLEBRAND FACTOR	BAXTER INTERNATIONAL INC; BAXTER HEALTHCARE SA
5510	BP5510USD3	United States	14/549404	20-Nov-2014			METHODS OF MEASURING ADAMTS13-MEDIATED IN VIVO CLEAVAGE OF VON WILLEBRAND FACTOR AND USES THEREOF	BAXTER INTERNATIONAL INC; BAXTER HEALTHCARE SA
5510	BP5510USD1	United States	13/795214	12-Mar-2013	8,623,612	7-Jan-14	METHOD FOR TESTING TREATMENT OF ADAMTS13 DEFICIENCY	BAXTER INTERNATIONAL INC; BAXTER HEALTHCARE SA